Vilnius, Lithuania, and Solna, Sweden – February 06, 2020 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Swedish biotech company Affibody, announced today that they signed a Manufacturing & Supply Agreement.
Under the scope of this agreement, Northway Biotechpharma will manufacture cGMP batches of the Drug Substance, a therapeutic protein, for Phase 2 clinical studies. After the process was previously transferred to Northway Biotechpharma which has produced cGMP batches for Affibody´s clinical Phase 1 study, both parties have decided to extend their cooperation.
“We are very proud to be part of the continuing development of this exciting project and that we can support Affibody with further cGMP manufacturing for their Phase 2 needs,” said Prof. Vladas Bumelis, Executive Chairman of the Board of Northway Biotechpharma.
Dr. André Markmann, VP Business Development for Europe of Northway Biotechpharma, informed “Since we started the cooperation with Affibody on their therapeutic candidate, the technology transfer, scale-up and cGMP manufacturing have been extremely successful. We are therefore very happy that Affibody honors our cooperation by signing a supply agreement for their Phase 2 requirements.”
“We appreciate the flexible nature of our collaboration with Northway Biotechpharma and looking forward to a successful continuation of the cooperation.”, said David Bejker, CEO of Affibody.
About Affibody - https://www.affibody.se
Affibody is a clinical-stage Swedish biotech company with a broad product pipeline focused on developing innovative bi- and multi-specific next-generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical-stage programs. The first two are therapeutic programs that target psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.
About Northway Biotechpharma
Northway Biotechpharma is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facility while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotechpharma is a privately owned company founded in 2004 and located in Vilnius, Lithuania.
For Further Information Contact: bd@northwaybiotech.com
Press release PDF
Please find our press release offered for download in a PDF form below:
NBPTH and Affibody sign a new CDMO agreement
